This new study will investigate if new therapies have resulted in better outcomes related to brain function in young hemophilia patients.
This new approval represents an expansion of the therapy's initial VWD indication, which was granted by the FDA in 2009.
NHF’s Physical Therapist of the Year Award is named in honor of Donna Boone.
Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy is free and avaliable for continung education credits.
The findings of this prevalence-based study could have significant future implications.
Shelby Dietrich, MD, helped establish one of the first hemophilia treatment centers in the US.
The AAVs being being investigated are designed to target the human liver, drawing on the organs potential to produce clotting factor.
The findings of a new study suggest several areas of impact relevant to adherence and physical activity for patients with severe hemophilia A.
Only one lot of Mononine® is included in this recall, all others are unaffected.
The opening of hemophilia B gene therapy trials to patients with little to no access to conventional treatments would be a pioneering advancement.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car